Owing to the absence of effective targets, systematic chemotherapy remains the mainstay of TNBC patients 9. The 5-year overall survival (OS) rate is about 80% in Chinese women 7, 8. TNBC patients often have poor clinical outcomes due to the high risk of early relapse and visceral metastases within 5 years 6.
This subtype represents 15–20% of all breast cancers in Chinese women 4 and is more common in patients with younger age, African-American race, and BRCA1 germline mutations 5. Triple-negative breast cancer (TNBC), defined by a lack of expression of estrogen receptor (ER), progesterone receptor (PR) expression, and human epidermal growth factor receptor 2 (HER2), is the most aggressive subtype among breast cancers 2, 3. Conclusively, our findings provided novel insights into the anti-oncogenic mechanism of MCPIP1, suggesting that MCPIP1 could serve as an alternative treatment target in TNBC.īreast cancer is the most common malignancy and the fourth leading cause of cancer-related deaths among women in China, accounting for 19.9% of all cancer diagnosed and 9.9% of all cancer-associated deaths in females in 2020 1. Subsequently, we showed that CTF5 participated in MCPIP1-mediated antiproliferative effect by transcriptionally repressing cyclin D1 expression, as well as downregulating its downstream signaling targets p-Rb and E2F1. Furthermore, we demonstrated that MCPIP1 modulated NFIC AS to promote CTF5 synthesis, which acted as a negative regulator in TNBC cells. Mechanistically, MCPIP1 was first demonstrated to act as a splicing factor to regulate AS in TNBC cells. We demonstrated that MCPIP1 overexpression dramatically suppressed cell cycle progression and proliferation of TNBC cells in vitro and repressed tumor growth in vivo. Here, we showed that MCPIP1 was downregulated in 80 TNBC tissues and five TNBC cell lines compared to adjacent paracancerous tissues and one human immortalized breast epithelial cell line, while its high expression levels were associated with increased overall survival in TNBC patients. Monocyte chemotactic protein induced protein 1 (MCPIP1), a zinc finger RBP, functions as a tumor suppressor in many cancers. AS is generally controlled by AS-associated RNA binding proteins (RBPs). Recently, emerging evidence suggested that aberrant alternative splicing (AS) plays a crucial role in tumorigenesis and progression.
Alternatively spliced transcript variants have been described.Triple-negative breast cancer (TNBC) is the most aggressive subtype with the worst prognosis and the highest metastatic and recurrence potential, which represents 15–20% of all breast cancers in Chinese females, and the 5-year overall survival rate is about 80% in Chinese women. The encoded protein mediates activation of various kinases and may function in cytokine and growth factor receptor signaling and cellular transformation. This gene encodes a member of the SH2-domain containing mediators family. Zgc:158474 antibody, SH2B3 antibody, PSM antibody, SH2B antibody, AI425885 antibody, C530001K22Rik antibody, Irip antibody, SH2-B antibody, SH2-Bb antibody, Sh2bpsm1 antibody, mKIAA1299 antibody, Sh2-b antibody, Sh2b antibody, SH2B adaptor protein 1 antibody, SH2B1 antibody, sh2b1 antibody, Sh2b1 antibody Antibodies should not be exposed to prolonged high temperatures. As with all antibodies care should be taken to avoid repeated freeze thaw cycles. Store at 4☌ for three months and -20☌, stable for up to one year. This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only. Supplied in PBS with 0.09 % (W/V) sodium azide. Custom Recombinant Antibody (rAbs) Services.Annexin V-FITC Apoptosis Detection Kits.
0 kommentar(er)
